<DOC>
	<DOCNO>NCT02579616</DOCNO>
	<brief_summary>This multicenter , single arm , open-label study participant unresectable BTC disease progression failure follow one prior gemcitabine-based doublet chemotherapy regimen ( combination gemcitabine cisplatin , gemcitabine platinum agent/fluoropyrimidine agent ) . This study contain 3 phase : Pre-treatment phase last within 21 day ; Treatment phase consist study treatment cycle tumor assessment conduct every 6-8 week ; Follow-up phase begin immediately Off-Treatment Visit continue long participant alive , unless participant withdraws consent , End Study .</brief_summary>
	<brief_title>Study Lenvatinib ( E7080 ) Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>1 . Pathologically cytologically confirm adenocarcinoma biliary tract cancer ( intrahepatic , extrahepatic cholangiocarcinoma , gall bladder cancer , ampulla Vater cancer ) 2 . Unresectable ( eg , locally advanced metastatic ) BTC 3 . One prior gemcitabinebased doublet chemotherapy ( eg , gemcitabine cisplatin ) unresectable BTC treat chemotherapy BTC Participants receive adjuvant chemotherapy eligible therapy complete recurrent show 6 month completion therapy 4 . Measurable disease meeting follow criterion : At least 1 lesion ≥ 1.0 cm long diameter nonlymph node ≥ 1.5 cm shortaxis diameter lymph node serially measurable accord Response Evaluation Criteria Solid Tumors 1.1 ( RECIST1.1 ) use computerize tomography/magnetic resonance imaging ( CT/MRI ) Lesions external beam radiotherapy ( EBRT ) locoregional therapy radiofrequency ( RF ) ablation must show evidence progressive disease base RECIST 1.1 deem target lesion 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 6 . Survival expectation 3 month longer begin study treatment 7 . Males females age ≥ 20 year time inform consent 8 . All chemotherapy radiationrelated toxicity must resolve Grade 01 per Common Terminology Criteria Adverse Events ( CTCAE v 4.03 ) , except alopecia , infertility , adverse event list inclusion criterion 9 . Adequately control blood pressure ( BP ) without antihypertensive medication ( define BP ≤ 150/90 mm Hg Screening change antihypertensive medication within 1 week prior first dose study drug ) 10 . Participants adequate function major organ blood coagulation : Absolute neutrophil count ( ANC ) ≥ 1500/mm^3 ( ≥ 1.5×103/μl ) Platelets ≥ 100,000/mm3 ( ≥ 100×10^9/L ) Hemoglobin ≥ 9.0 g/dL Bilirubin ≤ 2.0 mg/dL except unconjugated hyperbilirubinemia Gilbert 's syndrome Alkaline phosphatase ( ALP ) , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤ 3.0 × upper limit normal ( ULN ) ( ≤ 5.0 × ULN participant liver metastasis ) Creatinine clearance ≥ 40 mL/min per Cockcroft Gault formula Prothrombin timeInternational Normalized Ratio ( PTINR ) ≤ 1.5 11 . Participants must voluntarily agree provide write informed consent 12 . Participants must willing able comply aspect protocol 1 . Any anticancer treatment ( except BSC ) within 21 day prior first dose study drug 2 . Major surgery ( surgical procedure involve anesthesia respiratory assistance ) within 21 day prior first dose study drug schedule surgery study ( except bile duct drainage ) 3 . Ascites moderate , severe , require drainage 4 . Proteinuria ≥ 2+ dipstick testing ( Grade ≤ 1 confirmed quantitative assessment eligible ) 5 . Gastrointestinal malabsorption condition opinion investigator might affect absorption study drug 6 . New York Heart Association congestive heart failure class II , unstable angina , myocardial infarction , serious cardiac arrhythmia associate significant cardiovascular impairment within past 6 month first dose study drug 7 . A prolonged QT/QTc interval ( QTcF &gt; 480 m ) 8 . Known human immunodeficiency virus ( HIV ) positive 9 . Active infection require systemic treatment 10 . Bleeding thrombotic disorder chronic systemic use anticoagulant require therapeutic INR monitoring , eg , warfarin similar agent ( treatment low molecular weight heparin permit ) 11 . Gastrointestinal bleeding event active hemoptysis ( bright red blood least 0.5 teaspoon ) within 21 day prior first dose study drug 12 . Active malignancy ( except BTC definitively treat melanoma insitu , basal squamous cell carcinoma skin , carcinoma insitu cervix , early stage gastric/colorectal cancer ) within past 24 month prior first dose study drug 13 . Diagnosed meningeal carcinomatosis 14 . Participants brain subdural metastasis eligible , unless complete local therapy discontinue use corticosteroid indication least 28 day prior first dose study drug . Any sign ( eg , radiologic ) symptom brain metastasis must stable least 28 day prior first dose study drug . 15 . Known intolerance study drug excipients 16 . History drug alcohol dependency abuse within last 24 month prior first dose study drug 17 . Any medical condition opinion investigator ( ) would preclude participant 's participation clinical study 18 . Females breastfeed pregnant Screening Baseline ( document positive human chorionic gonadotropin [ hCG BhCG ] ) . A separate baseline assessment require negative screening pregnancy test obtain 3 day first dose study drug . 19 . For either male unless undergo successful vasectomy ( confirm azoospermia ) females childbearing potential , participant his/her partner agree use medically appropriate method contraception throughout entire study period use condom , contraceptive sponge , contraceptive foam , contraceptive jelly , diaphragm , intrauterine device , otherwise use oral contraceptive ( percutaneous transvaginal also allow ) least 28 day first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Lenvatinib</keyword>
	<keyword>E7080</keyword>
	<keyword>Unresectable biliary tract cancer</keyword>
	<keyword>BTC</keyword>
	<keyword>Gemcitabine-based combination chemotherapy</keyword>
	<keyword>Lenvima</keyword>
</DOC>